


User Guide Medtech32

New Zealand Formulary (BPACNZRx) Integration



(February 2020)



These release notes contain important information for Medtech32 users. Please ensure that they are circulated amongst all relevant staff. We suggest that this document is filed safely for future reference.

Contents

<u>What is BPACNZRx?</u>	<u>4</u>
<u>Restrictions of the BPACNZRx solution</u>	<u>5</u>
PREGNANCY WARNINGS ARE DISPLAYED REGARDLESS OF AGE	5
NO ABILITY TO SUPPRESS DRUGS 'AT RISK WHEN PREGNANT'	5
EXTENTION OF MEDICAL WARNINGS TO ALLOW 'OTHER SUBSTANCE' ALLERGIES TO BE RECORDED	5
NO CROSS-SENSITIVITY CHECKS	6
PRICE MAY BE INCORRECTLY DISPLAYED	6
ACTIVATION OF BPACNZRx IS AT DATABASE LEVEL NOT PRACTICE LEVEL	6
<u>Registration for activation of BPACNZRx</u>	<u>7</u>
<u>Activation of BPACNZRx</u>	<u>8</u>
ACTIVATING THE BPACNZRx NZF INTEGRATION FOR THE FIRST TIME	8
SWITCHING FROM BPACNZRx BACK TO MIMS	12
<u>Monthly Drug Updates</u>	<u>13</u>
<u>Drug Setup</u>	<u>15</u>
DRUG CLASS AND THERAPEUTIC OPTIONS	15
NZULM CODING	15
IMMP AND SPORT CATEGORIES	16
<u>Staff Setup</u>	<u>18</u>
ENABLE REPEAT SCRIPT WITHOUT OLD DRUG WARNINGS	18
DISPLAY WARNING FOR MILD PATIENT MEDICAL WARNINGS	18
INTERACTION WARNING MESSAGES	19
ACTION BASED INTERACTIONS	19
SEVERITY BASED INTERACTIONS	20
EVIDENCE BASED INTERACTIONS	21
<u>Medical Warnings</u>	<u>22</u>
MAPPING MIMS MEDICAL WARNINGS TO NZF MEDICAL WARNINGS	22
STEPS TO REMAP A MEDICAL WARNING	23
CREATING A NEW MEDICAL WARNING	31
MEDICATION AND OTHER SUBSTANCE PREDICTIVE SEARCHES	32
<u>Patient Medications</u>	<u>38</u>

MAPPING MIMS MEDICATIONS TO NZF MEDICATIONS	38
STEPS TO REMAP A MEDICATION RECORD WHEN SELECTED FOR REPEATING	39
NEW PATIENT MEDICATION	43
NZF DRUG TERMS	44
BPACNZRX LOGO	45
DRUG SEARCH	46
SECTION 29 DRUGS	50
MONOGRAPHS	51
INTERACTIONS	53
<u>Personal, Preferred and User-Defined Drugs</u>	<u>55</u>
PERSONAL MEDICINES	55
PREFERRED MEDICATION	55
USER-DEFINED DRUGS	55
<u>Reports</u>	<u>56</u>
DRUG USAGE REPORT	56
<u>GP2GP</u>	<u>56</u>
GP2GP PATIENT RECORD IMPORT	56
GP2GP PATIENT RECORD EXPORT	56
<u>Advanced Forms</u>	<u>57</u>
DISPLAY AND USE OF MEDICATIONS AND MEDICAL WARNINGS	57
<u>Third Party Integrations</u>	<u>57</u>
<u>ManageMyHealth & SEHR</u>	<u>58</u>
PATIENT MEDICATIONS DATA UPLOAD	58
PATIENT MEDICAL WARNING DATA UPLOAD	58
<u>PHO Clinical Event Export</u>	<u>59</u>
CLINICAL PERFORMANCE INDICATORS - STATINS	59
<u>New Zealand ePrescribing Service</u>	<u>59</u>
<u>Pharmac SA</u>	<u>59</u>
<u>Prescribing Assistant</u>	<u>59</u>

What is BPACNZRx?

Medtech32 now offers the NZF drug formulary as an alternative to the MIMS integrated formulary for prescribing and medical warnings. A practice can enable the NZF drug formulary as an alternative to the MIMS integrated formulary based on their choice as a practice. The NZF drug formulary aims to create the safest user friendly prescribing platform, and provides continued use of all existing prescribing functionality, where possible, along with additional features and functionality available based on the NZF drug data.

Medtech and BPAC NZ have enabled New Zealand Formulary integration into the Medtech32 platform. These integration and medical warning enhancements have been branded as BPACNZRx.

The MIMS and NZF integrated formularies mostly function in a similar fashion. The details below indicate significant differences when using BPACNZRx which includes aspects for consideration in regards to Patient Prescribing continuity:

- Drug-to-Drug Interaction checks utilise Stockley's Interaction Alerts engine, an internationally recognised accurate source of drug interactions.
- Medication terms may be longer, as these will be sourced from the NZ Universal List of Medicines.
- The ability to filter medication Unsafe in Pregnancy has been removed and has been replaced by always displaying a portion of the Pregnancy section of the associated medication monograph during prescribing.
- The Banned in Sports filter control to manage medications for athletes has been enhanced.
- Access to Medication Monograph information (i.e. NZ Formulary link) requires an internet connection.
- Section 29 medications are highlighted during the prescribing process and printed on a prescription.
- It was recognised that "Alert Fatigue" amongst prescribing clinicians is very real. This affects clinicians by conditioning them to ignore the many and frequent warnings which at times can feel unhelpful. BPACNZRx allows less important drug-to-drug interactions, such as 'Information only' to be suppressed (at individual prescriber level).
- BPACNZRx has also added a new mandatory medication alert field called "Severity". When prescribing a medicine classified with severe allergy, a Clinician will receive a warning prompt and be prevented from prescribing the medication.
- Whilst all medication warnings must be re-classified, clinicians also have the option of viewing and editing warnings during the prescribing process, as well as choosing to display or suppress warnings for allergies classed as mild.
- Patient drug allergies checks now include Excipient substances within the medication.
- BPACNZRx is committed to continually enhancing its capacity and speed. Monthly updates can be downloaded directly from within Medtech32.

Restrictions of the BPACNZRx solution

There are a number of restrictions that should be understood with regards to the use of the BPACNZRx integrated New Zealand Formulary data within Medtech32:

Pregnancy warnings are displayed regardless of age

Pregnancy monograph information displays for all patients regardless of their age or gender (This is important as some medications may affect male fertility) in this release of BPACNZRx. BPACNZRx may introduce user controlled settings in future releases to allow a provider to set the age boundaries for presenting the pregnancy warnings.

No ability to suppress drugs 'at risk when pregnant'

The approach of using pregnancy risk categories has several limitations, including that:

- It does not provide information about risks across different trimesters of pregnancy
- Medicines with a wide range of associated risks could be included in the same category
- The categories imply a grading system, which could lead to prescribing based on the risk category rather than an understanding of the evidence of risks and benefits for a particular patient
- The single-letter classification system does not provide enough information to support informed decision making by prescribers and patients

As a result of these shortcomings, there is an international movement away from using pregnancy safety categories, and in their place providing descriptions, where applicable, of the underlying evidence, degree of severity, timing of effects on the developing foetus and areas where there is a lack of evidence.

BPACNZRx includes brief advice on the safety of medicines in pregnancy and lactation from the textbook 'Drugs in Pregnancy and Lactation 2017' (used by permission from Wolters Kluwer Health). This information is available in an expandable section in a medicine monograph.

Extension of Medical Warnings to allow 'Other Substance' allergies to be recorded

Substances which are contained within medications can be located within the Generic Name category such as peanuts/arachis oil, egg, soy oil & almond oil etc.

However, non-medicinal substance allergies can also be recorded within Other Substances such as Cow's milk, Fish & pollen etc.

Recording of these allergies may reveal relationships between medication & other substance allergies.

No cross-sensitivity checks

Alerting groups do not provide cross-reactivity drug checks in this release of BPACNZRx. BPACNZRx is reviewing the group structure and may add these checks in future releases.

Price may be incorrectly displayed

If prescribers identify any incorrect pricing information they are encouraged to report this to the NZ Formulary via their feedback page <https://nzf.org.nz/Feedback> However prices for non-subsidised products should not be relied on due to the difficulty in maintaining up to date pricing.

Activation of BPACNZRx is at Database Level not Practice Level

If your practice shares a database with other practices, all practices will be activated when switching to BPACNZRx.

Registration for activation of BPACNZRx

All practices looking to adopt the BPACNZRx New Zealand Formulary Integration as an alternative to the MIMS drug formulary are required to register for the service before activation within Medtech32.

Practices are requested to **contact BPAC directly on 0800 633 236 or email contact@bpacnzrx.org** to complete the registration process.

The practice's **HPI Organisation Id will be required** as part of the registration process along with details of the number of prescribing PMS users and enrolled patients, and administrator contact details.

Once registration has been completed with BPAC, practices can complete the activation process of BPACNZRx within the Medtech32 application.

Important Note – De-activation of MIMS

It is the responsibility of a practice when activating BPACNZRx within Medtech32 to advise MIMS that the practice will no longer be a MIMS Subscriber. From this point the Practice will not be advised of any future MIMS monthly drug updates.


BPAC will notify customers when the monthly drug update is available.

Activation of BPACNZRx

Activating the BPACNZRx NZF integration for the first time


Help ► About Drug Formulary

The **About MIMS** menu item from the Help menu drop-down has been changed to **About Drug Formulary**. Through the **About Drug Formulary** menu an organisation can choose either the BPACNZRx (NZF) or MIMS drug formulary for activation.




To activate BPACNZRx drug formulary:


1. Ensure you are logged into Medtech32 as a user with System Admin access rights
2. Select Help > About Drug Formulary
3. Select the BPACNZRx option under the 'Drug Formulary Selection' section
4. View the 'New Zealand Formulary Website T & C's' by selecting the provided link
5. Click on the 'Register' button




6. A registration validity check will be performed and if the registration is found to be valid, the following prompt will display.



7. The Register button will update to 'Run BPACNZRx Drug Update'.



8. Click on the 'Run BPACNZRx Drug Update' button to start the file download process.
9. Once the download has completed, BPACNZRx Activation prompt will be displayed with details of the pre-requisites necessary before the activation of BPACNZRx




Important Note – Activation Process Information

Activation of BPACNZRx should be treated as a system upgrade and therefore all other users must be logged out of Medtech32 at the time of activation. The activation process may take some time to complete and is dependent on the size of the database, and as such it is recommended that activation of BPACNZRx be completed at a time where the practice is not required to be operational for a period of time.



Please ensure all pre-requisite requirements are completed before completing the activation of the BPACNZRx functionality.

It is recommended that you perform an Interbase Back Up and Restore process prior to your practice activating BPACNZRx if one has not been completed recently. The following prompt will be displayed during the Activation process as a reminder.




Clicking on OK to this message will continue the activation process.


- 10. After ensuring all of the pre-requisites are completed, click on the Yes option to continue with the BPACNZRx activation. The BPACNZRx Activation Process will be performed and the NZF Drug Update installed.



11. Once the NZF Drug Update and BPACNZRx Activation Process has been completed click on OK to the information prompt displayed.



12. The following MIMS Removal Information prompt will be displayed



These details will be automatically saved into the Medtech32 database and remain accessible from the Help > About Drug Formulary window by clicking on the 'MIMS Removal Information' button should MIMS require evidence of this action in relation to their Terms & Conditions.



13. Click on OK to close the Information prompt

After BPACNZRx activation the MIMS drug database will no longer be accessible, however, historical patient medications and medical warnings will still be displayed.

To view all of the changes to the Medtech32 application and the prescribing and medical warning changes on the patient record you must log out and back into Medtech32.


Important Note – BPACNZRx Registration

If during the BPACNZRx activation it is identified that your practice does not have a valid registration you will be prompted with a messaging advising that your ‘Organisation’s BPACNZRx registration is no longer current’

If this occurs, please contact BPAC NZ on 0800 633 236 or email contact@bpac.org.nz to renew or establish your registration for BPACNZRx

Important Note – NZF Monthly Update Download

If the download of the NZF Monthly Update fails due to user access to the download location the following message will be displayed:



Please contact your practice IT Support for assistance in ensuring that you have access to the specified location and try the NZF Monthly Update download process again once access has been provided.

Switching from BPACNZRx back to MIMS

If the situation arises where your practice would like to change from the BPACNZRx integrated formulary back to the MIMS drug formulary you are advised to contact the Medtech Support Team to discuss the process for the activation of MIMS.

It is recommended that before contacting Medtech Support you complete the following:

1. Contact MIMS to re-establish the practice's MIMS Subscription, and obtain Registration details
2. Download and have available the latest MIMS drug formulary (Full Installation) from the MIMS website for Medtech32

Monthly Drug Updates


Help ► About Drug Formulary OR Tools ► Clinical ► Drug Update

The NZF Monthly Download availability will be advised to registered practices by BPAC directly as soon as the monthly update is available.


The NZF monthly drug updates can be downloaded and performed directly from the About > Drug Formulary window within the Medtech32 application.

To download and install the NZF monthly drug update:

1. Ensure you are logged into Medtech32 as a user with System Admin access rights
2. Select Help > About Drug Formulary
3. Select the BPACNZRx tab
4. Click on the 'Run BPACNZRx Drug Update' button




5. The download of the most recent monthly drug formulary will commence
6. Once the NZF Monthly Drug Update has downloaded, the following prompt will be displayed:




If you would like to complete the Drug Update at this time:

7. Clicking on the 'Yes' option will continue to perform the Drug Update



8. Once the NZF Drug Update process has been completed click on OK to the information prompt displayed.



If you would like to complete the Drug Update at a later date:

9. Clicking on the 'No' option will close the Drug Update screen and return you to the About > Drug Formulary window. Click on OK to close the screen.
10. When you are ready to complete the Drug Update, repeat the same process as described above. The Tools > Clinical > Drug Update feature has been removed when BPACNZRx is activated.

Important Note – NZF Monthly Update Download

If the download of the NZF Monthly Update fails due to the practice's BPACNZRx registration having expired you will be prompted with a message advising that your 'BPACNZRx user registration has expired, and your medications information may be out of date'.

If this occurs, please contact BPAC NZ on 0800 633 236 or email contact@bpac.org.nz to renew or establish your registration for BPACNZRx

In addition all users should be logged out of Medtech32 during the Drug Update process.

Drug Setup


Setup ► Clinical ► Drug

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the Drug Setup screen:


Drug Class and Therapeutic Options

The **Therapeutic Options** tab has been removed as there is no information in the BPACNZRx NZF drug data to support this function. The **Drug Class** tab has been renamed **Alerting Group** and acts in a similar fashion by grouping medications for patient Medical Warning purposes.

Previous MIMS New/View Drug screen



New BPACNZRx New/View Drug screen




NZULM Coding


The NZULM (Universal List of Medications) are responsible for the allocation new product codes as new products are introduced by Pharmac. This code is utilised as part of the NZePS prescribing. They also provision the product prescribing term which is utilised within BPACNZRx.

Within the **Coding** tab provision has been made to display the NZULM product code.

Both the MPUU (Medicinal Product Unit of Use) and TPUU (Trade Product Unit of Use) NZULM codes are displayed for reference.



Where the selected product is available in the form of a 'Pack' then both the MPP (Medicinal Product Pack) and TPP (Trade Product Pack) NZULM codes are displayed for reference.




To learn more about the NZULM, please refer to: <http://info.nzulm.org.nz/>


IMMP and Sport Categories

Within the **More** tab the IMMP (Intensive Medicine Monitoring Programme) option has been removed as IMMP is not available to either the NZF or MIMS drug formularies.

Previous MIMS New/View Drug screen



The Sports Category list has also been updated to display the World Anti-Doping Agency (WADA) Sports Categories, which allows more granular drug filtering when prescribing.



To learn more about the NZF Sport Categories, please refer to: https://nzf.org.nz/nzf_239

Staff Setup


Setup ► Staff ► Members ► Provider Messages tab

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the Staff Setup screen:


Enable Repeat Script without Old Drug Warnings

Within the Provider Messages tab, the **Enable Repeat Script without Old Drug Warnings** option has been removed. This is to ensure that users are not able to repeat prescriptions for old / unmapped MIMS medications by overriding the prompt to re-map to the equivalent NZF medication.

Previous MIMS New/View Staff screen



New BPACNZRx New/View Staff screen



Display warning for MILD patient Medical Warnings


Within the Provider Messages tab, a new **Display warning for MILD patient Medical Warnings** option has been added. This is to ensure that users are prompted with a Medical Warning alert message even when the medical warning being presented is of Mild Severity.

By default this option is selected for all providers and can be unselected if the provider does not want to receive MILD patient Medical Warning alert prompts.




Interaction Warning Messages

The level of Drug Interactions that are displayed to a prescriber when prescribing using BPACNZRx can be configured at an individual level. By default the 'Display All Interaction Warnings' option will be applied to all prescribers.



By selecting the 'Display specific Interaction Warnings' option the level of interactions to be displayed can be specified by selecting relevant sub-codes.



Action based Interactions




- **Avoid:** For interactions where a drug combination is best avoided. This will mainly be used to highlight contraindicated drug pairs.
- **Adjust:** For interactions where the interaction can be accommodated, but where it is recommended that either one of the drugs is changed, or the dose is altered on initiating the combination.
- **Monitor:** For interactions where the drug pair is valuable and no compensatory action is possible, but the patient needs to be monitored to assess the outcome. For interactions where biochemical or therapeutic drug monitoring is recommended and further action may be needed based on the results.
- **Information:** For interactions where close follow up or monitoring are probably not automatically warranted due to the low probability of an interaction, but where more information is given in the event of a problem.

- **No action:** For interactions where no action is needed, or for drugs pairs where no interaction occurs.

Important Note – Action Based Interactions

For clinical safety reasons Avoid and Adjust action codes cannot be suppressed.

Severity based Interactions




- **Severe:** For interactions that could totally incapacitate a patient or result in either a permanent detrimental effect or a life-threatening event.
- **Unknown:** To be used only as a last resort. Designed for those interactions (such as the antiretrovirals), which are predicted but where there is insufficient evidence to even hazard a guess at the outcome.
- **Moderate:** For interactions that could result in an effect that may either cause considerable distress or partially incapacitate a patient. These interactions are unlikely to be life-threatening or result in long-term effects.
- **Mild:** For interactions that could result in an effect that is mild and unlikely to unduly concern or incapacitate the majority of patients
- **Nothing expected:** For interactions that are unlikely to result in an effect, or for drugs pairs where no interaction occurs.

Important Note – Severity Based Interactions

For clinical safety reasons Severe and Unknown severity codes cannot be suppressed.

Evidence based Interactions



- **Extensive:** For interactions where the information given is based on numerous small or medium size studies or several large studies. The information is usually supported by case reports.
- **Study:** For interactions where the information given is based on formal study. This may be one small or medium size study, or several small studies. The studies may or may not be supported by case reports.
- **Case:** For interactions where the information given is based either on a single case report or a limited number of case reports. No trials appear to have been conducted.
- **Theoretical:** For interactions where the information given is based on a theoretical interaction or lack of interaction. This information may have been derived either from in vitro studies involving the drug in question or based on the way other members of the same group act.

Careful consideration should be given before suppressing alerts for prescribers and should be relative to their experience.

Should a prescriber wish to view any interactions which have been suppressed the easiest method would be to utilise the Interactions feature available on the NZF website, www.nzf.org.nz.

Medical Warnings


Mapping MIMS Medical Warnings to NZF Medical Warnings

Module ► Clinical ► Medical Warnings

Following activation of BPACNZRx, existing MIMS Medical Warnings for a patient will be mapped and converted to the equivalent NZF Medical Warnings. Where the existing MIMS Medical Warnings are unable to be mapped and converted, the patient Medical Warnings will be retained in the Medical Warning list, and will be displayed in bold italic font, unless the patient has No Known Allergies (NKA) recorded or they have Note Only Medical Warnings recorded.

Date of Onset	Medical Warning	Severity	Note
18 Apr 2019			Peanut
<i>18 Aug 2017</i>	<i>benzylpenicillin</i>		
<i>18 Aug 2017</i>	<i>acetic acid</i>		
<i>05 Jul 2017</i>	<i>Penems</i>		
<i>03 Nov 2016</i>	<i>Penicillamine</i>		

Double clicking on a patient medical warning that is currently displayed in bold italics in the patient Medical Warning list will prompt the user with the following message:




Once this is understood, you can disable this message by selecting the 'Do not display this information again' option.



Clicking on OK will open the View Medical Warning screen for re-mapping to be completed. If there is only one un-validated medical warning then this is opened automatically for updating.

At this stage BPACNZRx does not have combined medications for selection within medical warnings such as co-trimoxazole. If a patient has a recorded allergy for this medication then a medical warning should be created for BOTH active substances, namely Sulfamethoxazole & Trimethoprim.




This mapping of the existing MIMS based Medical Warnings to new NZF based Medical Warnings is a pre-requisite for BPACNZRx prescribing to ensure patient Medical Warnings are displayed appropriately during prescribing of related medications.

Steps to remap a Medical Warning

On selecting and opening an existing MIMS based Medical Warning for a patient that requires mapping to an NZF based Medical Warning check and complete the following actions:


1. Confirm Date of Onset

The Medical Warning Date field has been renamed to Date of Onset. Therefore it is important that you check the accuracy of this date and change it if necessary to better reflect when the adverse reaction was first observed.



2. Re-map the new Medical Warning Type

To assist in selecting the new Medical Warning Type for the patient Medical Warning the existing MIMS based Medical Warning information has been retained on the Medical Warning screen for all Medical Warnings that were unable to be mapped and converted to the equivalent NZF Medical Warnings during the activation of BPACNZRx.




To remap the existing MIMS Medical Warnings select the Type of Medical Warning that is most appropriate for the patient Medical Warning.

Select from either Medication (e.g. Penicillin), Other Substance (e.g. Peanut or bee venom) or Other Important Note (e.g. Poor medication adherence) depending on the type of allergy that the patient has indicated or presented with.





If the Medical Warning type is selected as Medication:

If Medication is selected then select the sub-category of either Alerting Group or Generic Name.




Use the ellipsis button to search and find the appropriate Medication Alerting Group or Generic Name which is applicable. If known it is recommended to use Generic Name.






If the Medical Warning type Other Substance is selected:

If the existing MIMS Medical Warning was related to Food, Animals or other Environmental substances it should be mapped within the Other Substance Medical Warning type.



Use the ellipsis button to search and find the appropriate Substance which is applicable.



Before creating an Other Substance medical warning a check should be made to ensure the substance does not exist within the Generic Name category, such as Peanut, Soy & Egg allergies.

In addition, should a patient have an intolerance to an intra uterine device (IUD) this can be located within the Other Substance list. But it is important to realise Other Substance allergies are NOT checked during the prescribing process, only Alerting Group & Generic Name medical warnings are checked.


If the Medical Warning type is selected as Other Important Note:

We recognise that many clinicians have used the Medical Warnings module to record miscellaneous information unrelated to Medications or Other Substances.

If the Other Important Note Medical Warning type is selected then enter the description in free text Note field provided.



The contents of the OLD Note field for the existing MIMS Medical Warning will automatically be displayed in the new NZF Medical Warning note field.



Important Note – Other Important Notes field

We recognise that many clinicians have used the Medical Warnings module to record miscellaneous information unrelated to Medications or Other Substances. Medtech recommends that you Do NOT enter Medication related Medical Warnings on to the patient’s medical record using the Other Important Note option as this will introduce clinical risk to the patient when prescribing. Ensure for Medication related Medical Warnings that the Medication option is selected.

3. Assign Severity

Recording Severity is a new and important categorisation for the patient's Medical Warning. Recording of a Severity is mandatory in all Medical Warnings.

A clinical judgement is required in relation to the patient's reaction to the drug or substance. The severity of the allergy can be selected as either Mild, Moderate or Severe.

- **Severe** - this should be selected if the Medical Warning is Life-Threatening or severe enough for the drug/substance not to be prescribed or the patient not be exposed to the substance.
- **Moderate** – this should be selected if the Medical Warning is moderate or not severe enough and the drug/substance can be prescribed again if deemed necessary. It is an alert that indicates alternatives should be considered but may be ignored based on clinical judgement.
- **Mild** – this should be selected if the Medical Warning is mild or tolerable for the patient, allowing the warning to be ignored if necessary in conjunction with clinical judgement. It is an alert that may either be ignored and/or indicates that alternatives should be considered.

Important Note – Medical Warning Severity

If you mark the allergy/warning as Severe (i.e. life-threatening reaction) then in the interest of patient safety the system will prevent accidental prescribing of medications associated with the selected Generic Name or Alerting Group.

4. Check Medical Warning Notes

The contents of the OLD Note field for the existing MIMS Medical Warning will automatically be displayed in the new NZF Medical Warning note field.

Important Note – Medical Warning Notes

Patients may have a number of Medication based Note Only Medical Warnings which presents a clinical risk when prescribing. Therefore it is recommended the prescriber takes opportunity to reclassify them as Medication based Medical Warnings, so they are only displayed where applicable during prescribing, rather than viewing them for every medication which occurs when Rx Warning is ticked.

5. Check the Rx Warning status

For Other Substance or Other Important Note Medical Warning types indicate if you DO NOT want it displayed when prescribing by unticking the Rx Warning option.

Once the re-mapping of the Medical Warning appears valid, click on the OK to save the updated Medical Warning to the patient record.

During the save process the following information message will be presented to the user advising them that a medical warning for the specific medication has been created, and will prompt alert messages at the time of prescribing, including for all associated medications contained within the same Alerting Group:

If the updated Medical Warning was marked with a Severity of Severe, the following information prompt will also be displayed:


The Medical Warning will no longer be displayed in bold italics within the Medical Warning list for the patient and provided there are no more patient Medical Warnings displayed in bold italics, prescribing will be permitted for the patient.

Date of Onset	Medical Warning	Severity	Note
04 Nov 1998	amoxicillin	Severe	Rash on arm

Clicking on Cancel in the View Medical Warning screen at any point during the re-mapping process will discard your changes and return you to the Medical Warning list screen for the patient.

Important Note – Medical Warning list screen

The patient Medical Warning list screen will no longer be displayed in created Date Order. It will instead be displayed in Severity Order of Severe, Moderate and Mild.



Date of Onset	Medical Warning	Severity	Note
04 Nov 1998	amoxicillin	Severe	Rash on arm
23 May 2019	penciclovir	Moderate	
23 May 2019	Animal feed	Mild	Sickness

Important Note – Re-mapping prior to eReferral or GP2GP transfer

The existing MIMS Medical Warnings for a patient DO NOT need to be re-mapped should a patient require an eReferral or a GP2GP record transfer to be completed before further prescribing within BPACNZRx.

Creating a New Medical Warning

Module ► Clinical ► Medical Warnings ► New

The accurate recording of a Patient Medical Warning is critical for the continued well-being of a patient, especially in the areas of allergies to Medications and Vaccines.

Recording a Medical Warning helps ensure the patient is not prescribed a medication or administered a vaccine that may have an adverse effect on the patient's health.

Important Note – Recording of Vaccine Allergies

There is currently no link with Vaccine allergies and the Immunisation module. The patient's Medical Warning list must be manually checked PRIOR to administering a Vaccine.

The Medical Warnings in BPACNZRx has been designed to allow creation of medical warnings more effectively and efficiently via the use of radio buttons and predictive searching.


The screenshot shows a 'New Medical Warning' dialog box. It has a title bar with a close button. Below the title bar are two tabs: 'Main' and 'Audit'. The 'Date of Onset' is set to '22 Aug 2019'. Under the 'Type' section, there are three radio buttons: 'Medication' (selected), 'Other Substance', and 'Other Important Note'. Under the 'Generic Name' section, there are two radio buttons: 'Generic Name' (selected) and 'Alerting Group'. The 'Generic Name' field is empty with an ellipsis button. The 'Severity' section has three radio buttons: 'Mild', 'Moderate', and 'Severe'. The 'Note' field is empty. The 'Provider' dropdown is set to 'Sam Eaves (SFE)'. The 'Inactive' checkbox is unchecked. 'OK' and 'Cancel' buttons are at the bottom right.

Date of Onset: the date the allergy event is identified should be recorded; this field defaults to the current day's date but can be changed when creating the Medical Warning.

Type: select the type of Medical Warning according to the type of allergy. The following types are available:

- **Medication:** to select the required generic drug name or the Alerting Group, type the first few letters of the Generic medication name or Alerting Group of the drug in the field then press the ellipsis button to display potential matches. The search criteria can be further refined if what you are looking for is not displayed. In doing so the displayed results are automatically updated. Highlight the required term from the listing and press the Enter key to select or the ok button. The selected term will be displayed in the Medication field of the Medical Warnings screen.
- **Other Substance:** to select the required substance, type the first few letters of the substance name of the drug in the Keywords field then press the Search or press the Enter key to display potential matches. Highlight the required substance name from the listing and press the Enter key to select. The selected substance name will be displayed in the Substance field of the Medical Warnings screen.

- Other Important Note:** This should ONLY be used if the Medical Warning does not fit in to either of the above two categories. **To include allergy related information within this category could introduce clinical risks for the patient and should be avoided.** For example a patient could have an Other Important Note and a No Known Allergies recorded, hence if the Note contains allergy information then the patient records are in conflict and will introduce clinical risk for the patient.
- No Known Drug Allergies (NKA):** this option will only be present in the Medical Warning module if the patient has no ACTIVE Medical Warnings, excluding Other Important Notes. On opening the New Medical Warning screen, it will automatically default to the No Known Allergies option.




If the No Known Allergies option is selected for a patient, the 'Note' field will be automatically updated with the text (NKA).


If a patient Medication or Other Substance Medical Warning is subsequently added, the No Known Allergies warning is automatically removed from the patient Medical Warnings and does not require manual removal.

Medication and Other Substance Predictive Searches


A predictive searching feature has been introduced in both the Find Generic Name & Alerting Group (Medication Medical Warning types) and Find Substance (Other Substance Medical Warning type) screens which automatically displays matches based on what is entered in the search field. For example, if A is entered in the search field all names beginning with A will be displayed resulting in a reduced number of mouse clicks.



As more characters are entered into the screen, fewer results are automatically displayed.



When searching for Other Substances, the most common allergic substances are displayed at the top of the list in alphabetical order, therefore, if the patient has a common allergy, no search criteria is required.



Severity: three levels of Severity can be specified; this requires clinical judgment in relation to the patient's reaction to the drug or substance.

- **Severe** - this should be selected if the Medical Warning is Life-Threatening or severe enough for the substance not to be prescribed (system checks are limited to Peanuts & Eggs based products) or the patient not be exposed to the substance.
- **Moderate** – this should be selected if the Medical Warning is moderate or not severe enough and the substance can be prescribed again if necessary. It is an alert that indicates alternatives should be considered but may be ignored based on clinical judgement.
- **Mild** – this should be selected if the Medical Warning is mild or tolerable for the patient, allowing the warning to be ignored if necessary in conjunction with clinical judgement.

It is an alert that may either be ignored and/or indicates that alternatives should be considered.

Severity of Medical Warnings is a new feature with radio buttons alongside the grading of Mild, Moderate and Severe, which can be applied to Medications.

There is no default value of Severity for a New Medical Warning and must be selected based on clinical judgement.

Medication Other Substance Other Important Note
 Generic Name Alerting Group
 Generic Name: benzylpenicillin
 Severity: Mild Moderate Severe
 Note:
 Provider: Sam Eaves (SFE)
 Inactive:

Once a severity value is selected (e.g. Mild), it will be emphasised in bold font and the other values are left inconspicuous.

Generic Name:
 Severity: **Mild** Moderate Severe
 Note:



When Severe is selected, it is emphasised in red bold font.

Generic Name:
 Severity: Mild Moderate **Severe**
 Note:

Important Note – Medical Warning Severity


If you mark the allergy/warning as Severe (i.e. life-threatening reaction) then in the interest of patient safety the system will prevent accidental prescribing of medications.

If a severity of Moderate or Mild is selected then a warning prompt is displayed during prescribing to help ensure it is not overlooked.




However, the Mild warning prompt can be suppressed within staff setup but it will still be displayed in the Interactions/Warnings area when prescribing.

As with medication allergies/intolerances, the Severity level can also be set for Other Substances. If the Other Substance Medical Warnings need to be displayed during prescribing then Rx Warning must be ticked.



However, if deemed clinically necessary, the severity value of the medical warning can be altered by double clicking the relevant medical warning in the prescribing interaction grid.




Note: should it be necessary to add additional information in relation to the Medical Warning that is not covered in the other fields, it can be entered here.

Rx Warning: this field only appears when a Type of Other Substance or Other Important Notes is selected and is ticked by default. If this field remains ticked then the Other Substance or Other Important Note Medical Warning will be displayed within the Rx Interactions section when prescribing any medication.


Provider: specify the staff member who recorded the patient Medical Warning. This will default to the logged in Provider.

After entering the required details, clicking OK will apply validation rules and save the Medical Warning to the patient record.

During the save process the following information message will be presented to the user if they have selected a Medical Warning type of 'Medication' advising them that a medical warning for the specific medication has been created, and will prompt alert messages at the time of prescribing:



If the new Medical Warning was marked with a severity level of Severe, the following information prompt will also be displayed:



Patient Medications

Mapping MIMS Medications to NZF Medications

Module ► Clinical ► Patient Medications

Following activation of BPACNZRx, existing MIMS Medication records for a patient will be mapped and converted to the equivalent NZF Medication records. Where the existing MIMS Medication records are unable to be mapped and converted, the patient Medications will be retained in the Patient Medication list. They will, however, be displayed in italic font and will be unable to be automatically repeated for the patient.

Rep	Date	Drug Name	Qty	Directions
<input type="checkbox"/>	26 Mar 2018	Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input checked="" type="checkbox"/>	26 Mar 2018	Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input type="checkbox"/>	26 Mar 2018	Atorvastatin 10mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	26 Jan 2018	Simvastatin 10mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	5 Dec 2018	Rivaroxaban 10mg Tab [15]	12	1 tabs, Three Times Daily
<input type="checkbox"/>	<i>24 Aug 2018</i>	<i>Midazolam Maleate 7.5mg Tab</i>	0	
<input type="checkbox"/>	24 Aug 2018	Lorazepam 4mg/1ml Inj (section 29)	0	
<input type="checkbox"/>	24 Aug 2018	Diazepam 10mg/10ml Elixir (section 29)	12	1, Three Times Daily
<input type="checkbox"/>	15 Aug 2018	Warfarin Sodium 1mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	12 Feb 2018	Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input type="checkbox"/>	18 Jan 2018	Penicillamine 125mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	28 Nov 2017	Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input type="checkbox"/>	<i>28 Nov 2017</i>	<i>Paracetamol 120mg/5ml Oral Susp</i>	15	<i>15 ml, Immediately</i>
<input type="checkbox"/>	15 Nov 2017	Panadol 125mg Supp	0	25 sup, Immediately
<input type="checkbox"/>	15 Nov 2017	Amoxicillin 250mg Cap	12	1 caps, Three Times Daily

The mapping of the existing MIMS Medication records to new NZF based Medication records is a pre-requisite for BPACNZRx prescribing when repeating medications to ensure that during the repeating process a Medication for a patient is able to be successfully recorded and that all related Medical Warnings are displayed appropriately during prescribing of related medications.

Important Note – Repeating un-mapped (italic) Patient Medications

All existing MIMS based Medication records selected for repeating for a patient that are unmapped must be reclassified to the equivalent NZF Medication during the repeat prescribing process to avoid potential prescribing errors.

Please be aware that any patient Medications that are displayed in italics are not recognised by the Drug to Drug Interaction checks performed when prescribing.

Steps to remap a Medication record when selected for repeating

Selecting to repeat an existing MIMS based Medication (or multiple Medications) that requires mapping to an NZF based Medication (medication displayed in italics) will require you to check and complete the following actions:

1. Select patient Medications to Repeat

Select an existing MIMS based Medication (or multiple Medications) to repeat for a patient that requires mapping to an NZF based Medication. The existing MIMS based Medications that require mapping are those that are displayed in italics in the Patient Medication list.

Rep Date	Drug Name	Qty	Directions
<input type="checkbox"/>	26 Mar 2018 Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input checked="" type="checkbox"/>	26 Mar 2018 Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input type="checkbox"/>	26 Mar 2018 Atorvastatin 10mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	26 Jan 2018 Simvastatin 10mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	5 Dec 2018 Rivaroxaban 10mg Tab [15]	12	1 tabs, Three Times Daily
<input checked="" type="checkbox"/>	24 Aug 2018 Miconazole Maleate 2.5mg Tab	0	
<input type="checkbox"/>	24 Aug 2018 Lorazepam 4mg/1ml Inj (section 29)	0	
<input type="checkbox"/>	24 Aug 2018 Diazepam 10mg/10ml Elixir (section 29)	12	1, Three Times Daily
<input type="checkbox"/>	15 Aug 2018 Warfarin Sodium 1mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	12 Feb 2018 Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input type="checkbox"/>	18 Jan 2018 Penicillamine 125mg Tab	12	1 tabs, Three Times Daily
<input type="checkbox"/>	28 Nov 2017 Amoxicillin 250mg Cap	12	1 caps, Three Times Daily
<input checked="" type="checkbox"/>	28 Nov 2017 Paracetamol 1.21mg/5ml Oral Susp	15	15 mls, Immediately
<input type="checkbox"/>	15 Nov 2017 Panadol 125mg Supp	0	25 sup, Immediately
<input type="checkbox"/>	15 Nov 2017 Amoxicillin 250mg Cap	12	1 caps, Three Times Daily

2. Use the Drug Map screen to identify the closest NZF based Medication

On trying to repeat an existing MIMS based patient Medication (displayed in italics), the closest NZF based Medication matches will be listed for selection.

WARNING
Quetiapine Fumarate
 This medication is from the old database and cannot be prescribed.
 Please select a new medication from the list of alternatives below or click 'Search' to select from the full drug list.
 Copy prescribing details from old medication

SA Drugs: Subsidised:

Exclude drugs in sports prohibited at All times in Competition only in selected sports [Rx Safety Info](#)


Brand/Generic	Form	Brand	Sub
Quetiapine 100 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE	
Quetiapine 100 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE	
Quetiapine 100 Mg Tablet (Seroquel)	Tablet	SEROQUEL	
Quetiapine 100 Mg Tablet (Quetapel)	Tablet	QUETAPEL	
Quetiapine 200 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE	
Quetiapine 200 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE	
Quetiapine 200 Mg Tablet (Seroquel)	Tablet	SEROQUEL	
Quetiapine 200 Mg Tablet (Quetapel)	Tablet	QUETAPEL	
Quetiapine 25 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE	
Quetiapine 25 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE	
Quetiapine 25 Mg Tablet (Seroquel)	Tablet	SEROQUEL	

Strength	Price	PML
quetiapine 25 mg tablet	1.79	
quetiapine 100 mg tablet	0.00	
quetiapine 200 mg tablet	0.00	
quetiapine 300 mg tablet	0.00	

Buttons: OK Brand NZF Search Cancel Help

Select the most suitable NZF based medication and strength (if it is not the one that has been selected automatically for you).


The checkbox 'Copy prescribing details from old medication' is ticked by default to preserve dosage, frequency, period, mitte and classification values in the existing MIMS based patient Medication record.




(OR)

2. Use the Drug Search screen to identify the closest NZF based Medication

If there are no suitable NZF based Medication matches, then the **Drug Search** window can be launched by clicking the 'Search' button at the bottom of the Drug Map screen.



Select the most suitable NZF based medication and strength.



The checkbox 'Copy prescribing details from old medication' is ticked by default on the Drug Map screen which was opened prior to the Drug Search screen to preserve dosage, frequency, period, mitte and classification values in the existing MIMS based patient Medication record.

Important Note – Selection of Medication Strength

Care must be taken if you are selecting a Medication with a different strength. If this occurs default prescribing details/instructions for the Patient Medication will need to be altered appropriately.

3. Save the change in Medication name

Once the selection of the most suitable NZF based medication and strength has been completed click on the OK button to save the change from the MIMS based Medication to the selected NZF based Medication.

Strength	Brand	Price	PML
quetiapine 25 mg tablet	Quetapel	1.79	
quetiapine 150 mg tablet	Auro-Quetiapine	0.00	
quetiapine 200 mg tablet	Auro-Quetiapine	0.00	
quetiapine 300 mg tablet	Auro-Quetiapine	0.00	

Add To Alternatives List

 Brand
 Add...
 NZF
 Cancel
 Help

The New Patient Medication screen will be displayed, presenting the selected NZF based medication.

New Patient Medication GMS: A4

Main | Audit

Drug: Quetiapine 25 Mg Tablet

Dosage: 1 tablet Freq: Three Times Daily (TDS) Period: 5 days

Mitte: 15 tablet Amount: 49.67

Directions: 1 tablet, Three Times Daily

Repeats: 0 Options...

Administer: oral Administered in Clinic

Initial Dispensing Period: days Provider Eligible for Co-Payment

Provider: Sam Eaves (SFE) Prescribed Externally

Date of Issue: 27 May 2019 External Provider:

Classification: Confidential Long Term

Status: Generic Substitution

Recommended by Specialist Patient meets Endorsement Criteria

Specialist: Date Recommended:

Previous Drug: Quetiapine Fumarate

Interactions **Severe Allergy: Peanut "Shock"**


3 Warnings Pregnancy: Pregnancy: Compatible|Maternal Benefit >> Embryo-Fetal Risk: Preg

Severe Interactions between: Quetiapine 25 Mg Tablet; Viagra Inf


Add to Personal NZF

4. Check and complete the Medication directions

Check and complete the administration directions for the selected NZF based medication to ensure that they are correct. Where possible the dosage, frequency, period and mitte values in the existing MIMS based patient Medication record will be displayed by default.




The 'Previous Drug' field will display the name of the previous MIMS based patient Medication that was selected before the change to the NZF based patient Medication.




5. Review Interaction Warning for the new Patient Medication

Once you have checked and completed the administration directions for the new Patient Medication review any Interaction Warnings that may be presented to you.



6. Save the change in Medication record

Once you have reviewed any Interaction Warnings for the new Patient Medication that may be presented to you click on the OK button to save the new NZF based Medication.



This will complete the repeating process for the Patient Medication, and make it available for any further re-prescribing in the Patient's Medication list.

Rep	Date	Drug Name	Qty
<input type="checkbox"/>	25 May 2019	Quetiapine 25 Mg Tablet	12
<input type="checkbox"/>	18 Aug 2017	<i>Quetiapine Fumarate</i>	7
<input type="checkbox"/>	8 Apr 2014	<i>Paraffin</i>	5


Important Note – Presentation on the Drug Map screen

The Drug Map screen will be presented for each of the patient Medications selected for repeating that are existing MIMS based Medication records that are yet to be reclassified to the equivalent NZF Medication. The process for mapping a patient Medication must be completed for each of the Medications one by one.

New Patient Medication

Module ► Clinical ► New Prescriptions


When the prescriber opens the prescribing screen for the first time after migrating to BPACNZRx, and the selected patient has unmapped Medical Warnings the following warning message will be displayed when selecting to create a New Prescription:



If the selected patient has multiple unmapped Medical Warnings in their patient record, on clicking OK, the Medical Warnings grid will be opened automatically.

Date of Onset	Medical Warning	Severity	Note
18 Apr 2019			Peanut
18 Aug 2017	<i>benzylpenicillin</i>		
18 Aug 2017	<i>acetic acid</i>		
05 Jul 2017	<i>Penems</i>		
03 Nov 2016	<i>Penicillamine</i>		

If the selected patient has a single unmapped Medical Warning in their patient record, on clicking OK, the View Medical Warning will be opened automatically.



On clicking Cancel, the prescribing process will be cancelled and the warning message will be closed.


Important Note – Medical Warning Mapping

All existing MIMS based Medical Warnings for a patient that are unmapped must be reclassified to the equivalent NZF Medical Warning and the Severity value set before prescribing for the patient is permitted to avoid potential prescribing errors.

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the New Patient Medication screen:


NZF Drug Terms

The new NZF drug terms used for the BPACNZRx prescribing module may be longer than the previous MIMS drug terms as they include the component substances along with their respective strengths within a particular preparation.



Due to the long drug term, the full description of the drug may not be visible in the Drug field in the New Patient Medication screen when prescribing.


Should it be necessary to view the full NZF drug name, the field can be expanded by dragging the right side border of the New Patient Medications window. This feature also applies to **Directions** and **Interactions**.




The size of the New Patient Medication Window will be remembered if 'Remember Screen Size' configuration is enabled for the user in Staff Setup.

BPACNZRx logo

The BPACNZRx logo will display in the Interaction Warning section at the bottom of the New Patient Medication screen when no Interaction Warning messages are displayed.



Clicking on the BPACNZRx logo will open the NZ Formulary website <http://www.nzformulary.org/> in the user default web browser.



Drug Search


When searching for a medication to prescribe to the patient, the Drug Search screen will now perform the drug search within the NZF drug database.

The following itemises the changes to the Drug Search screen for the BPACNZRx prescribing module:

- Search by 'Therapeutic Options' has been removed from both the Quick and Advanced tabs


- The 'Sub' filter has been renamed to its full term 'Subsidised'

- Exclude 'Unsafe in Pregnancy' filter has been removed, as the pregnancy related information from the monograph will be displaying during prescribing which can be double clicked to open the monograph section to view the full contents.
- 'Exclude Banned in Sport' filter has been removed, and has been replaced with a new set of filter options which follow the World Anti-Doping Agency (WADA) classification of three categories:
 - Exclude drugs prohibited in sports at all times
 - Excluded in selected sports
 - Excluded in competition only



If a patient is a competitive athlete & subject to drug testing, then the 'Exclude drugs prohibited in sports at all times' must be checked. If they are an athlete in an eye/hand coordinated sport, which bans beta blockers, then the 'in selected sports' must be checked. Finally, if they are in competition or are about to compete, then 'in competition' must ALSO be checked.


Clicking on the Help icon next to the new Sport filters will open and display Guidance on using these new filter controls.



- A new 'Rx Safety Info' feature has been added to the Drug Search screen.

The Rx Safety Info feature is an important new feature which can be used to ensure a drug is not contra-indicated in hepatic and renal impairment, pregnancy and breast-feeding.

Clicking on the Rx Safety Info button on the Drug Search screen after selecting a medication will open the NZF Safety Information screen.




As the 'Unsafe in Pregnancy' filter has been removed, it is important that a prescriber refers to the 'Rx Safety Info' section carefully before prescribing.

Important Note – NZF Safety Information

Unlike MIMS the NZF Safety Information is not stored locally in the practice’s system. The NZF Safety Information is an online web-based resource, and requires an internet connection to be accessed. Being an online resource you can be assured that the information is as up to date as possible when using it, even if the latest drug update has not been run.


- Search by Therapeutic Group on the Advanced tab now provides a drill down to three levels of ATC (Anatomical Therapeutic Chemical) and is presented in a tree hierarchy



- The first level of the code indicates the anatomical main group
- The second level of the code indicates the therapeutic main group
- The third level of the code indicates the therapeutic/pharmacological sub-group

Please Note: Some levels may not display any medications which means no drugs are currently available within NZ that belong to the selected category.

- The ‘Generic Group’ option on the Advanced tab has been renamed to ‘Generic Name’



- Searching for all the preparations for a particular drug name will show the list of preparations in order of Strength.

Drug Search

Quick | Advanced

Drug Name: PARACETAMOL 125 Search

Personal | Brand/Generic Include Inactive

SA Drugs: Subsidised

Exclude drugs prohibited in sports at all times in selected sports in Competition Rx Safety Info

Brand/Generic	Form	Brand	Sub
Paracetamol 125 Mg Suppository (Panadol)	Suppository	PANADOL	
Paracetamol 125 Mg Suppository (Paracetamol (Pharmacy Health))	Suppository	PARACETAMOL (PHARMACY HEA...	
Paracetamol (Pharmacy Health) - Paracetamol 125 Mg Suppository	Suppository	PARACETAMOL (PHARMACY HEA...	
Paracetamol 125 Mg Suppository (Gacet)	Suppository	GACET	

Strength	Brand	Price	PKML
paracetamol 125 mg suppository	Gacet	3.29	
paracetamol 125 mg suppository	Paracetamol (Pharmacy Health)	0.00	
paracetamol 250 mg suppository	Paracetamol (Pharmacy Health)	0.00	
paracetamol 500 mg suppository	Paracetamol (Pharmacy Health)	0.00	

Add To Alternatives List

OK Brand Add NZF Cancel Help

In the interests of clinical safety and to assist in avoiding Prescribing errors, all medication 'sets' will be ordered by strength in ascending order, where the lowest strength is to be at the top and the highest at the bottom.

In addition, to support the predominantly prescribed subsidised medications, the subsidised medication will be selected by default within the strength grid which suppresses other non-subsidised equivalents to be displayed.

Brand/Generic	Form	Brand	Sub
Amoxicillin 100 Mg/MI Oral Liquid: Powder For (Amoxil Paediatric Drops)	MI	AMOXIL PAEDIATRIC DROPS	
Amoxil Paediatric Drops - Amoxicillin 100 Mg/MI Oral Liquid: Powder For	MI	AMOXIL PAEDIATRIC DROPS	
Amoxicillin 125 Mg/5 MI + Clavulanic Acid 31.25 Mg/5 MI Oral Liquid: Powder For	MI	ALPHA-AMOXICYCLAV	
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Moxlin)	MI	MOXLIN	
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Miloxly 125)	MI	MILOSLY 125	
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Amoxicillin Actavis)	MI	AMOXICILLIN ACTAVIS	
Amoxicillin Actavis - Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For	MI	AMOXICILLIN ACTAVIS	
Amoxicillin 250 Mg Injection: Powder For (Amoxil)	Vial	AMOXIL	
Amoxil - Amoxicillin 250 Mg Injection: Powder For	Vial	AMOXIL	
Amoxicillin 250 Mg/5 MI + Clavulanic Acid 62.5 Mg/5 MI Oral Liquid: Powder For	MI	ALPHA-AMOXICYCLAV	
Amoxicillin 250 Mg/5 MI Oral Liquid: Powder For (Amoxicillin Actavis)	MI	AMOXICILLIN ACTAVIS	


Strength	Brand	Price	PKML
amoxicillin 125 mg/5 mL oral liquid: powder for	Miloxly 125	0.00	
amoxicillin 125 mg/5 mL oral liquid: powder for	Alphamox	1.20	

Prescribe OK Brand Add NZF Cancel Help

Section 29 Drugs

For Section 29 drugs, the term 'Section 29' is generally not included in the NZF drug term as it has been previously displayed for MIMS drug terms. Instead for Section 29 drugs you will now see the indicator displayed in bold blue font above the Drug field in the New Patient Medication screen.

Previous MIMS New/View Drug screen





New BPACNZRx New/View Drug screen



Section 29 is also printed on the prescription for the attention of the Pharmacist Dispenser.


Monographs

The full NZF monographs can be accessed through the NZF button at the bottom of the New Patient Medications and Drug Search Window.




There are separate monographs available within the NZF for adults (blue header) and children (red header).


The type of monograph opened is predicated on the age of the selected patient recorded in the Patient Register. If the patient is aged 17 years or younger, the child monograph is opened.



If the patient is older than 17 years of age, the adult monograph is launched.




You can switch between the adult and child monographs by selecting the blue or red banner at the top of the NZF Medicine Information screen.



Important Note – Monograph Terms and Conditions

On accessing the NZF Monographs for the first time the user will be presented with the 'Welcome to the New Zealand Medicine Formulary' page. Please review and accept the Terms and Conditions for use of the NZF formulary before proceeding by clicking on the Accept button.




This message will display once for NZF Adult Monographs and once for NZF Child Monographs.

Please Note: If the NZF button is selected from the New Patient Medication screen and the patient is 17 years or younger the monograph automatically positions at the Dosage section for quick access.

Interactions


The interactions grid will display Medical Warnings, pregnancy related information and the drug and Drug to Drug Interactions.



The ordering of Interaction warnings displayed on the New Patient Medication screen will be:

- Patient Medical Warnings, related to the prescribed drug if any, ordered by Severity
- Other Substance Medical warnings with Rx Warning ticked, ordered by Severity
- Patient Note Only with Rx Warning ticked, ordered by date created, oldest at the top
- Pregnancy section from NZF monograph
- Drug to Drug interactions, ordered by Severity

Each of the strings of interaction information can be double clicked to get further details (e.g. pregnancy string and/or drug or drug to drug interaction information) or alternatively click the Details button when the relevant information is highlighted.



When these pop-out windows are displayed they can be sized & positioned to suit. If 'Remember Screen Size' configuration is enabled for the user in Staff Setup, then they are displayed as configured next time they are opened.

For a Medication or Other Important Note interaction warning, double clicking will open the relevant View Medical Warnings screen providing the ability to edit or change the medical warning such as changing the Severity of the Medical Warning from the Interaction display or marking it Inactive if it is no longer relevant to the patient or it is a duplicate.

New Patient Medication GMS: A4Z

Main | Audit

Drug: Warfarin Sodium 5 Mg Tablet

Dosage: Freq: Period:

Mitte: Amount:

View Medical Warning

Main | Audit

Date of Onset:

Medication **Other Substance** Other Important Note

Substance:

Severity: Mild Moderate **Severe**

Note:

Rx Warning:

Provider:

Inactive:

Interactions Severe Allergy: Peanut ****

3 Warnings

Suppress

Severe Interactions between: Warfarin Sodium 5 Mg Tablet: A

Add to Personal

Personal, Preferred and User-Defined Drugs

Personal Medicines

Setup ► Clinical ► Personal Medicines

Only Personal Medications which have been mapped automatically to NZ Formulary drugs will be available for prescribing after BPACNZRx activation.


Any Personal Medications that were created using MIMS drugs or historic Pharmac medications that could not be mapped to NZ Formulary drugs will no longer be available for prescribing after BPACNZRx activation and will need to be created as a new Personal Medications using the NZ Formulary drugs.

Preferred Medication

Setup ► Clinical ► Drug

As part of the BPACNZRx activation, the existing MIMS drug formulary is removed from the Medtech32 application. The selection of any MIMS drug as a 'Preferred Medication' will not be retained when the data is removed from Medtech32.

A provider must reinstate the Preferred Medication flags on the equivalent NZ Formulary drugs through the Setup > Clinical > Drug screen, and selecting the 'Preferred' option on the Coding tab for any drugs that they would like to be displayed as a Preferred medication.



User-Defined Drugs

Setup ► Clinical ► Drug

All currently configured User-Defined Drugs will be available for prescribing after BPACNZRx activation.

If a User-Defined Drug was mapped to a MIMS Generic Group (or Drug Class) previously in the Generics tab of the Setup > Clinical > Drug screen, it will need to be re-mapped to the equivalent NZF Generic Name (or NZF Alerting Group) after activation of BPACNZRx to ensure they can be suitably recognised when performing a patient Medical Warning cross check during prescribing. If no Generic Name or Alerting Group is specified no medical warning checks are possible.

Reports

Drug Usage Report

Report ► Clinical ► Drug Usage Report

The Drug Usage Report will continue to function after activation of BPACNZRx.

Practices should, however, be aware that the Drug Usage Report will only report on drugs from the current drug formulary in use, being either MIMS or NZF.

It is recommended, if necessary, to run the Drug Usage Report prior to BPACNZRx activation to generate the report on any MIMS drug usage. Post activation, the report will only display NZF drug usage.

GP2GP

GP2GP Patient Record Import

Module ► Inbox ► Provider Inbox (or) Tools ► Patient ► GP2GP Patient Record Manual Import

The GP2GP Patient Record Import will continue to function after activation of BPACNZRx.

The GP2GP Patient Record Import has been enhanced to recognise NZULM (New Zealand Universal List of Medicines) codes. This will reduce the number of medications that are displayed in italics within the Patient Medication list after a GP2GP Patient Record import is completed, improving the ability to repeat the medication for the patient, provided the sending system passes NZULM codes.

GP2GP Patient Record Export

Tools ► Patient ► GP2GP Patient Record Export

The GP2GP Patient Record Export will continue to function after activation of BPACNZRx.

The GP2GP Patient Record Export has been enhanced to include NZULM (New Zealand Universal List of Medicines) codes. This will allow other Patient Management Systems to recognise Medications and Medical Warnings, regardless of the drug formulary in use.

Advanced Forms

Display and use of Medications and Medical Warnings

Module ► Advanced Forms

Medtech has been working with all known and approved Third Party Integrators that supply Advanced Forms utilising the Medtech database to practices. All third party Advanced Forms that are known to Medtech should continue to retrieve and display Patient Medication and Medical Warnings information after upgrade.

Medtech advises that you contact your Third Party Advanced Form providers to ensure that they have made any necessary changes to support the new Medtech database structure prior to upgrade prior to activation of BPACNZRx.

Medtech has provided a technical document that provides a summary of the changes, identifying both new and updated database tables for Third Parties that integrate into these areas of the Medtech32 application which can be downloaded from the Insight Customer Portal via the following link:

<https://insight.medtechglobal.com/downloads/medtech32-resources/>

Third Party Integrations

Medtech has been working with all known and approved Third Party Integrators that supply integrated modules utilising the Medtech database to practices. All third party integrations that are known to Medtech should continue to retrieve Patient Medication and Medical Warnings information after upgrade.

Medtech advises that you contact your Third Party integrators to ensure that they have made any necessary changes to support the new Medtech database structure prior to upgrade prior to activation of BPACNZRx.

Medtech has provided a technical document that provides a summary of the changes, identifying both new and updated database tables for Third Parties that integrate into these areas of the Medtech32 application which can be downloaded from the Insight Customer Portal via the following link:

<https://insight.medtechglobal.com/downloads/medtech32-resources/>

ManageMyHealth & SEHR

Patient Medications Data Upload

The patient Medications data upload to ManageMyHealth and the SEHR will continue to function after activation of BPACNZRx.

Request Repeat Prescription (RRP) messages coming from ManageMyHealth into Medtech32 will continue to function with BPACNZRx.

Patient Medical Warning Data Upload

The patient Medical Warning data upload to ManageMyHealth and the SEHR will continue to function after activation of BPACNZRx.

Important Note – Patient Education on Medication and Medical Warnings

Practices should be aware that the Medication and Medical Warning data displayed to a patient on the ManageMyHealth portal will change post activation of BPACNZRx. As Medications and Medical Warnings are re-mapped from the MIMS drug formulary to its equivalent in the NZF drug formulary the updated record will be uploaded to the patient's record on ManageMyHealth. A patient may query the change in the Medication names or Medical Warning names, and as such a practice may need to consider patient education around these changes.

Important Note – Request Repeat Prescription (RRP) Messages

If a patient has requested a repeat of their Medications which includes existing MIMS Medications and Medical Warnings that are yet to be mapped and converted to NZF Medications and Medical Warnings, the provider will be prompted with the Drug Mapping and/or Medical Warning screens during the Repeat Medication process. The provider will be required to complete the remapping processes before the Request Repeat Prescription (RRP) process can be completed. However, as it is assumed repeating medications should not introduce clinical risks this step can be optionally bypassed in the interest of time.

PHO Clinical Event Export

Clinical Performance Indicators - Statins

Utilities ► LinkTech ► PHO Clinical Event

The PHO Clinical Event Export will continue to function after activation of BPACNZRx.

The 'CVD risk recorded as $\geq 15\%$, prescribed statins' query performed as part of the PHO Clinical Event Export has been updated to ensure that both MIMS and NZF statin drugs are considered as part of the data collection.

Specifically for NZF, the inclusion of drugs that have an ATC Code which STARTS with C10AA or C10BA or equal to A10BH51.

New Zealand ePrescribing Service

Module ► Clinical ► Patient ePrescriptions

The New Zealand ePrescribing Service will continue to function after activation of BPACNZRx.

Pharmac SA

Utilities ► Pharmac SA ► Pharmac SA

The Pharmac Special Authorities submission will continue to function after activation of BPACNZRx.

Prescribing Assistant

Module ► Clinical ► New Prescription

All medications for which Prescribing Assistant is triggered under the MIMS drug formulary (e.g. Dabigatran) will continue to function after activation of BPACNZRx.



Meet Sara – she's here to help!

Are you looking for a quick answer to your support query or changes related to this release?

Sara, our Virtual Support Chat Bot is available within our Insight Customer Portal 24 hours a day, 7 days a week, whenever you need help.

All you need to do is type a question, and Sara will provide the answer. She has been trained on most of the questions we get asked regularly on our Support Desk.

If Sara cannot answer your support query, she will assist you in creating a Support Ticket or can pass you onto a member of our Customer Care team.

If you would like to ask Sara your next support query, log into Insight at insight.medtechglobal.com